SEC Form 4 · accession 0001179110-17-013184
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher P Leamon
Officer — Vice President of Research
Period of report
Oct 4, 2017
Accepted (ET)
Oct 6, 2017 · 5:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 4, 2017 | A | 40,000 | $0.00 | A | 124,401 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents restricted stock units that will vest and be paid 1/2 annually over a period of 2 years beginning on October 4, 2018, in the form of one share of common stock for each restricted stock unit.
- F2Includes 2500 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on June 15, 2017.